Potential for clinical use of viable pluripotent progenitor cells in blood bank stored human umbilical cord blood.
There are indications that a close HLA match may not be necessary when human umbilical cord blood (HUCB) is used to effect a hematopoietic transplant. This was first suggested in 1972 and was further supported by the ability of HUCB to produce mouse survival following lethal irradiation. In China multiple units of HLA unmatched HUCB was utilized successfully in children to effect transplants. A recent publication indicated that newborn rodent blood cells can engraft in adult mice across the non-H-2 [corrected] antigens. Furthermore, there recently have been successful transplants with 3 antigens mismatched HUCB. In this study HUCB was stored in polyolefin blood bank bags at 4 degrees C. The storage was similar to that used in routine blood banking. Clonogenic assays were performed at Day 1 and 21 utilizing various growth factors. Replating efficiency was determined on colonies obtained from cord blood that was stored (non-frozen) for 21 days. The functional ability of day 21 old HUCB was determined by its ability to produce survival of lethally irradiated mice. It was found that approximately two-thirds (62.5%) of single primary blast cell colonies in day 21 stored HUCB could generate various types of secondary colonies. In some instances the secondary colonies were counted as high as 42 total mean colonies per single primary colony. These blast cell colonies (CFU-BL) were able to form single and multi lineage colonies composed of virtually every hematopoietic cell types. Animal survival studies were utilized in an effort to determine possible functional ability and were successful in producing fifty-day survival in 54% of lethally irradiated SJL/J mice and 100% ALB/C mice. This study holds the potential of making HUCB available for purposes of marrow transplantation to all who need it. It could further remove most of the moral and ethical issues related to HUCB, reduce to a fraction the cost in providing stem cells for marrow transplantation and potentially allow HUCB to be handled by existing blood banks.